In various tumor models, alrizomadlin is a pharmacological p53 activator that has been found to promote an antitumor microenvironment, sensitize tumors that are resistant to PD-1 blockade, and enhance the efficacy of a PD-1 blockade independent of p53 status [207]. This evidence concerns the gene TP53 and neoplasm.